Marketing leans on generic AI jargon, but the proposition is anchored by proprietary radar hardware and clinical evidence—so easy-to-copy analytics language is tempered by physical sensor moat.

Site claims 'Unsere KI' without naming third‑party models—signals likely proprietary analytics rather than thinly‑wrapped external LLMs.

Continuous 24/7 monitoring for falls, delirium and pressure ulcers positions the product as core to clinical routines and proactive care decisions.

An installed base of 150+ institutions shows real clinical distribution, but the site shows no ecosystem channels or platform partnerships to amplify reach.

Proprietary radar hardware plus a branded real‑time analytics pipeline implies substantial hardware‑software coupling and on‑site installation complexity.

Clinical focus, peer‑reviewed outcome evidence and privacy‑by‑design messaging provide strong enterprise credibility even without explicit compliance badges shown on the site.

Installed hardware, continuous monitoring, and demonstrated clinical outcomes create high data/hardware gravity and real replacement friction.

Clear deployment evidence and named customers indicate commercial traction, but hidden pricing and limited pricing transparency leave maturity ambiguous.

Vertical workflow products start safer than generic assistants.

Small downgrade to vulnerability — hardware, clinical evidence, installed base and high switching costs make QUMEA safer than its current score implies.

QUMEA – Foresight for Better Care.